On May 18, 2021 Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn" or the "Company"), a biopharmaceutical company currently focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders and monogenic diseases, reported that management will host a conference call on Tuesday, May 25, 2021 at 4:30 p.m. Eastern Time (ET) (Press release, Brooklyn ImmunoTherapeutics, MAY 18, 2021, View Source [SID1234580219]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Participants are asked to pre-register for the call through the following link: View Source Please note that registered participants will receive their dial in number upon registration and will dial directly into the call.

The conference call will also be available through a live webcast found here.

The Company invites participants to pre-submit questions to [email protected] until 5:00 p.m. Eastern Time (ET) on May 20, 2021 (live questions will not be accepted during the call). Please use the subject line, "BTX Call Questions" for this correspondence. The Company will do its best to address all pre-submitted questions at the conclusion of prepared remarks.